AZD3355
Sponsors
AstraZeneca
Conditions
Acid Reflux DiseaseGERDGastroesophageal Reflux DiseaseGastroesophageal Reflux Disease (GERD)HeartburnRefluxReflux DiseaseReflux Episodes
Phase 1
Drug Interaction Study Between AZD3355 and Nexium
CompletedNCT00684190
Start: 2008-03-31End: 2008-06-30Updated: 2010-12-03
Study to Compare Different Formulations of AZD3355
CompletedNCT00688402
Start: 2008-04-30End: 2008-06-30Target: 48Updated: 2010-12-03
AZD3355 Dose-escalation Study in Healthy Males
CompletedNCT00757419
Start: 2008-09-30End: 2008-12-31Target: 54Updated: 2010-12-07
Renal Impairment Study
CompletedNCT00863161
Start: 2009-03-31End: 2010-02-28Updated: 2011-01-24
Phase 2
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
CompletedNCT00394472
Start: 2006-11-30End: 2007-06-30Updated: 2013-03-18
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
CompletedNCT00703534
Start: 2008-05-31End: 2009-01-31Updated: 2011-06-20
TLESR-impedance Study in Patients
CompletedNCT00743444
Start: 2007-02-28End: 2008-02-29Updated: 2013-07-22
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
CompletedNCT01043185
Start: 2009-12-31End: 2010-05-31Updated: 2011-06-14